Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-and-extend aflibercept plus retinal photocoagulation for diabetic macular edema (extension study)
jRCTs031180356Completed
- Sponsor
- Bayer
- Start
- Sep 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Primary endpoints: Central retinal thickness and Visual acuity. Started Sep 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCTs031180356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180356.